Amarin Corp Plc - AMRN STOCK NEWS

Amarin Corporation (NASDAQ: AMRN) announced significant findings from an in vitro trial presented at the ACC’s 71st Annual Scientific Session. The study revealed that combinations of Eicosapentaenoic Acid (EPA) with statins—atorvastatin and rosuvastatin—reduced lipid oxidation by 86% and 75%, respectively (p<0.001). These results enhance the understanding of EPA's role in combating cardiovascular risks when paired with statins, aligning with previous REDUCE-IT trial results. The trial emphasizes potential benefits for high-risk patients needing stronger solutions.

Amarin Corporation plc (NASDAQ:AMRN) achieved a significant milestone by securing its first national reimbursement for VAZKEPA in Sweden, marking an important phase in its international expansion strategy. The Swedish Dental and Pharmaceutical Benefits Agency approved VAZKEPA for statin-treated patients with established cardiovascular disease at a monthly cost of 1,640 SEK. The company aims to expand its presence in several other European countries and is actively pursuing regulatory approvals in markets like Australia, New Zealand, and Saudi Arabia. This decision is expected to unlock significant revenue potential for Amarin.

Amarin Corporation has announced research on VASCEPA and VAZKEPA to be presented at the American College of Cardiology’s 71st Annual Scientific Session from April 2-4, 2022. Six posters will highlight findings related to the effectiveness of icosapent ethyl in reducing cardiovascular risks, particularly when combined with high-intensity statins. CEO Karim Mikhail expressed optimism about the continuous expansion of the evidence base regarding icosapent ethyl's potential role for high-risk patients.

Amarin Corporation announced that a new post hoc analysis of the REDUCE-IT study indicates that VASCEPA significantly reduces cardiovascular risks in patients with a history of percutaneous coronary intervention (PCI). The analysis showed a 34% reduction in major cardiovascular events, with absolute risk reductions of 8.5% and 5.4% for primary and secondary endpoints. In total, 3,408 patients were involved, where 37.6% on standard care had major events compared to 25.6% treated with VASCEPA. The findings support VASCEPA's role in reducing recurrent cardiovascular events in high-risk patients.

Amarin Corporation plc (NASDAQ:AMRN) reported a 2021 net revenue of $583.2 million, down 5% from 2020. The net product revenue was $580.3 million, impacted by generic competition and COVID-19 effects. In the U.S., the Go-To-Market strategy is progressing well, with expanded reach to 150,000 healthcare providers. Meanwhile, VAZKEPA has received approval in Europe, and Amarin is advancing regulatory filings in multiple countries. The company remains committed to enhancing cardiovascular outcomes and managing operational costs effectively. A conference call is scheduled for today at 8:00 a.m. ET.

Amarin Corporation (NASDAQ: AMRN) announced that CEO Karim Mikhail will participate in a virtual fireside chat at the Cowen 42nd Annual Health Care Conference on March 7, 2022, from 9:10 AM to 9:40 AM ET. Interested parties can access the live webcast on the company’s investor relations website, which will be archived for 30 days. Amarin focuses on innovative cardiovascular disease management and clinical trials, with a commitment to advancing treatment options.

MedStar Health Research Institute's analysis indicates that icosapent ethyl is cost-effective compared to standard care for high-risk patients with hypertriglyceridemia, both during the REDUCE-IT® clinical trial and in lifetime projections. The evaluation, published in JAMA Network Open, involved over 8,000 patients and demonstrated that icosapent ethyl led to more quality-adjusted life years (QALYs) than standard treatment. The study utilized detailed patient-level data, enhancing the rigor of its cost-effectiveness analysis.

Amarin Corporation plc (NASDAQ: AMRN) announced a conference call with senior management to discuss its fourth quarter and full year 2021 financial results on March 1, 2022, at 8:00 a.m. ET. This call will follow the release of the financial results earlier that day. Investors can access the call through the company’s investor relations website or by dialing in. Amarin focuses on cardiovascular disease management and aims to advance treatment beyond traditional therapies. The replay will be available for two weeks post-call.

Cyteir Therapeutics has appointed John F. Thero to its board of directors, expanding the board from eight to nine members. Thero, who brings over 30 years of experience in financial and operations roles, will chair the audit committee. He is recognized for leading Amarin through critical phases, including the launch of VASCEPA, and has received accolades such as Ernst & Young's Entrepreneur of the Year for Life Sciences. Thero expressed enthusiasm about contributing to Cyteir's growth, targeting advancements in their candidate CYT-0851 for oncology patients.